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Background. Ranibizumab is approved for treatment of macular edema in eyes with retinal vein occlusion (RVO). Some eyes show
low-response to treatmentwith regard to visual acuity gain (VA) andOCT central retinal thickness (CRT) reduction.The goal of this
study was to quantify the percentage of low-responders.Methods. Treatment of na¨ıve eyes with macular edema secondary to RVO
was included and monthly VA and CRT were analyzed. Four weeks after the loading phase, and at the end of the study, eyes were
grouped into low- and good responders based on predefined criteria.The responder and low-responder groups were then compared
at various time points. Results. Forty-three eyes were included. Regarding VA, 27.9% were low-responders after the loading phase
and 30.2% at the end of the study. For CRT, 34.9% were low-responders after the loading phase versus 27.9% at the end of the study.
75% of patients that were VA low-responders and 73.3% of CRT low-responders after loading phase remained low-responders at
the end of the study. Conclusion. Approximately 30% of patients showed low response to ranibizumab after the loading phase and
after 1 year of treatment. Two-thirds of patients that were low-responders after the loading phase remained low-responders after 1
year.
1. Background
Central retinal vein occlusion (CRVO) is characterized by
blockage of the major outflow vessel of the retina, resulting
in retinal hemorrhages, exudates, and macular edema [1]. In
branch retinal vein occlusion (BRVO), one of the primary,
secondary, or tertiary branches of the central retinal vein
are blocked [2]. BRVO leads to similar retinal problems and
visual loss due to macular edema if the posterior pole is
affected.
Intravitreal injection of ranibizumab (Lucentis; Genen-
tech, Inc., South San Francisco, CA), a Fab fragment that
binds all isoforms of VEGF-A, has been shown to markedly
reduce macular edema. Two large, multicenter, double-
masked trials—the Ranibizumab for the Treatment of Mac-
ular Edema following Branch Retinal Vein Occlusion Study
(BRAVO) [3] and the Ranibizumab for the Treatment of
Macular Edema after Central Retinal Vein Occlusion Study
(CRUISE) [4] analyzed the efficacy and safety of intravit-
real ranibizumab in either types of retinal vein occlusion.
The study results showed that intraocular injections of
ranibizumab were beneficial for these patients.
The HORIZON trial (ClinicalTrials.gov identifier:
NCT00379795) was designed to obtain additional informa-
tion about the long-term efficacy of ranibizumab treatment
in two patient cohorts. Cohort 1 included patients with neo-
vascular age-related macular degeneration and will not be
discussed further. Cohort 2 included patients with macular
edema after retinal vein occlusion that had completed the
BRAVO or CRUISE studies [5]. Recently, Bhisitkul et al.
reanalyzed data from BRAVO and CRUISE to see if optical
coherence tomography (OCT) data at baseline or month 3
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in the treatment of macular edema had predictive value to
differentiate between good and low-responders [6]. They
found that at month 3 of ranibizumab treatment, OCT
images provided predictive information for patients with
CRVO, but not for those with BRVO. Visual outcomes at
months 6 and 12 were reduced in patients with CRVO with
persistent macular edema at month 3.
The purpose of this study was to analyze data of “real-life”
patients outside a clinical trial setting to identify and differ-
entiate low-responders to ranibizumab treatment in eyes with
macular edema due to retinal vein occlusion.
2. Methods
For this observational, retrospective study, all charts of
patients treated at the Department of Ophthalmology,
Inselspital, University Hospital Bern, Switzerland, between
01/2010 and 09/2013 withmacular edema secondary to BRVO
or CRVO have been reviewed to identify eligible patients.
Inclusion criteria weremacular edema affecting the fovea due
to BRVO or CRVO that was treated with repeated injections
of ranibizumab. No other prior therapy for macular edema
was allowed because eyes that required a switch were already
considered as potential low-responder to the previous treat-
ment. All eyes received 3 consecutive injections in the first
3 months of treatment as a loading dose. Monthly follow-up
was done over a period of at least 12 months to avoid under-
treatment due to delayed examinations. After the loading
phase, patients received PRN treatment in case of edema
recurrence or new vision loss (>5 letters). At baseline and
each following month best-corrected ETDRS visual acuity
(VA) and OCT central retinal thickness (CRT, based on the
central area of the ETDRS grid) were measured. Final VA
and CRT were noted at month 12 or in case of an injection,
4 weeks after the last injection. For OCT retinal thickness
measurements, Spectralis OCT volume scans (Heidelberg
Engineering, Heidelberg, Germany) were used. The follow-
up function was used for repeated measurements. Patients
were categorized into a treatment responder and a low-
responder group based on VA and CRT change.The first cut-
off was made at month 4, four weeks after the loading phase
of three consecutive, monthly ranibizumab injections. The
second cut-off wasmade at the end of the observation period.
Responder and low-responder groups were then compared.
Eyes were characterized as low-responders if VA did not
increase >6 letters from baseline, which represents less than
50% of the expected VA gain extrapolated from the BRAVO
and CRUISE studies [3–5]. Eyes were also characterized as
low-responders if CRT did not decrease >30% from baseline.
VA low-responder and OCT low-responder were analyzed
separately.
GraphPad Prism software (version 5.02) was used for
statistical analysis. Group means of low-responders and
responders inVAandCRT at different time pointswere tested
with Student’s 𝑡-test. Differences between good responders
and low-responders were tested with the Chi-Square test.
𝑝 values <0.05 were considered statistically significant. All
values are presented as mean ± SD.
Table 1
VA responder at month 4 31 (72.1%)
VA responder end-of-study 30 (69.8%)
VA responder match 27 (87.1%)
VA low-responder at month 4 12 (27.9%)
VA low-responder at end-of-study 13 (30.2%)
VA low-responder match 9 (75%)
CRT responder at month 4 28 (65.1%)
CRT responder at end-of-study 31 (72.1%)
CRT responder match 27 (87.5%)
CRT low-responder at month 4 15 (34.9%)
CRT low-responder at end-of-study 12 (27.9%)
CTR low-responder match 11 (73.3%)
Distribution of responders and low-responders at month 4 and at the end
of study. Results are shown for visual acuity (VA low-responder = ≤6 letters
gain) and central retinal thickness (CRT low-responder = ≤30% decrease
in thickness). Patients that stayed within one group over the whole study
period were counted as a match. All values are given in 𝑛 (%).
The study followed the tenants of the Declaration of
Helsinki and was approved by the Cantonal Ethics Commit-
tee Berne.
3. Results
176 charts of patients with macular edema due to CRVO or
BRVO were identified. 43 eyes were included in the analysis
(22 cases of BRVO; 21 cases of CRVO; 19 females; mean
age 71.74 years ± 13.1). All other eyes have been excluded
because either theywere not treatment na¨ıve or treatmentwas
switched to other intravitreal therapy during the first year.
Mean baseline VA was 47.4±17.3 letters. Mean baseline CRT
was 588.7±193.9 𝜇m. Final VA increased to 64.0±17.2 letters
andCRTdecreased to 328.8±139.3 𝜇m.Differences inVAand
CRT change were significant (𝑝 < 0.0001). Table 1 shows the
distribution of patients in the responder and low-responder
groups at month 4 and at the end of study. Patients that were
low-responders at month 4 as well as at the end of study were
counted as a match. The same calculation was performed for
responder groups. Results are also shown in Table 1.
Figure 1 shows typical OCT scans at baseline and month
4 of one patient in the responder and another patient in
the low-responder group. Chi-square test revealed significant
differences within responder and low-responder groups at
month 4 and at the end of study for VA (𝑝 = 0.0002) and
CRT (𝑝 < 0.0001). The corresponding bar plots are shown in
Figure 2. Table 2 shows mean VA and CRT values at baseline,
after the loading phase and at the end of study as well as other
characteristics for responder and low-responder patients.
3.1. Subgroup Analysis Regarding VA Low-Responder. Group
comparison revealed that VA low-responders after the load-
ing phase required significantly more injections within the
first year of treatment (10 ± 2 versus 8.4 ± 2 injections; 𝑝 =
0.0067). VA low-responders after the loading phase started
with a significantly better baseline VA (58.5 ± 14.8 versus
43.1 ± 16.4 letters; 𝑝 = 0.027) compared to treatment
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Figure 1: (a) Branch retinal vein occlusion prior to therapy. Macular edema is present in the upper half of the macula. Corresponding color-
coded thickness map (middle) and ETDRS mean retinal thickness values are shown (left). (b) 4 weeks after the loading phase (3 monthly
injections of ranibizumab) the edema disappeared. Intraretinal exudates are still present. Central retinal thickness decreased from 331 to
241 𝜇m. ETDRS visual acuity improved from 42 to 75 letters. (c) OCT findings in central retinal vein occlusion prior to therapy. A larger
cyst can be appreciated in the foveal area. Central retinal thickness is 377𝜇m. (d) After the loading phase, central retinal thickness remained
virtually unchanged. The cystic appearance of the retina is still present. ETDRS visual acuity improved from 45 to 48 letters.
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Figure 2: Distribution of responder and low-responder at different time points during the study in regard to visual acuity (a) andOCT central
retinal thickness (b). The 𝑦-axis represents the actual number of patients in each group.
responders. Final visual acuity was significantly lower in the
VA low-responder group at the end of study (51.2 ± 15.0
versus 69.4 ± 15.6 letters; 𝑝 = 0.0173). In addition, low-
responders at the end of study already showed significantly
lower VA values after the loading phase (53.1 ± 16.1 versus
67.2 ± 13.5 letters; 𝑝 = 0.0061). Further, VA low-responders
after the loading phase had significantly lower VA values
compared to VA responders after the loading phase (56.5 ±
18.2 versus 65.6 ± 13.6 letters; 𝑝 = 0.031). At the end of
study, VA low-responders after the loading phase and at the
end of study showed significantly higher CRT values at the
end of study (final CRT for VA low-responder loading phase:
431 ± 194.5 𝜇m versus 289.2 ± 86.7 𝜇m; 𝑝 = 0.0216, and final
CRT for VA low-responder end of study: 417.7 ± 205.1 𝜇m
versus 297.6 ± 85.5 𝜇m; 𝑝 = 0.0443).
Finally, VA low-responders after the loading phase and at
the end of study showed significantly higher CRT values after
the loading phase (474.2 ± 242.3 𝜇m versus 281.0 ± 77.0 𝜇m;
𝑝 = 0.0003; and 464.7 ± 249.3 𝜇m versus 287.7 ± 77.4 𝜇m;
𝑝 = 0.001, resp.).
The distribution of BRVO and CRVO cases in the VA
low-responder group was equal (50%). Two low-responder
patients showed ischemic areas with capillary dropout in
the macula (16%; 1 BRVO, 1 CRVO) during fluorescein
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angiography, versus 4 patients in the responder group (13%, 3
CRVO, 1 BRVO).
3.2. Subgroup Analysis Regarding CRT Low-Responder. CRT
low-responder received a mean number of 9.2 injections
versus 8.8 injections in the nonresponders group. In addition,
CRT low-responders showed significantly higher CRT values
compared to responders after the loading phase (458.1 ±
226.9 𝜇m versus 268.9 ± 53.1 𝜇m; 𝑝 = 0.0001) and at the end
of study (471.9 ± 196.0 𝜇m versus 288.9 ± 87.9 𝜇m; 𝑝 = 0.05).
If patients were CRT low-responders already after the loading
phase, mean CRT values were also significantly higher at the
end of study (420.9 ± 279.4 𝜇m versus 279.4 ± 68.6 𝜇m; 𝑝 =
0.0083). In addition, CRT low-responders after the loading
phase showed significantly lower VA values after the loading
phase (57.6 ± 14.3 versus 66.0 ± 15.3 letters; 𝑝 = 0.0001).
CRT low-responders at the end of study already showed
significantly lower VA values after the loading phase (56.6 ±
13.1 versus 64.9 ± 14.7 letters; 𝑝 = 0.013).
In the CRT low-responder group, 55% of cases hadCRVO
and 45%BRVO.Two low-responder patients showedmacular
ischemia (18%; 1 BRVO, 1 CRVO), versus 4 patients in the
responder group (12%, 3 CRVO, 1 BRVO).
No other significant differences between the low-
responder and responder groups were found for age, baseline
VA, or baseline CRT.
4. Discussion
Low-response to antiVEGF treatment is frequently observed
in clinical routine. Just recently, Guber et al. described certain
clinical risk factors for low response to ranibizumab in
exsudative age-relatedmacular degeneration [7]. Formacular
edema secondary to retinal vein occlusion, it remains chal-
lenging to identify low-responders early during the treatment
process to avoid ineffective and expensive treatment without
significant benefit for the patient. Our analysis revealed
that, outside of the clinical setting of BRAVO and CRUISE
studies, approximately one-third of patients were classified
as low-responders for VA gain and CRT reduction after the
loading phase and after 1 year of treatment based on our low-
responder criteria. Approximately two-thirds of patients that
were low-responders for VA and CRT after the loading phase
and remained low-responders after 1 year of treatment.These
numbers appear to be in the same range as shown by Bhisitkul
et al. analyzing low response to ranibizumab treatment in the
BRAVO and CRUISE study population [6]. However, criteria
for low-response are not uniformly defined for response or
low-response in anti-VEGF treatment for macular edema
due to retinal vein occlusions. We defined VA low-response
as a VA gain of <6 EDTRS letters, which represents less
than 50% of the expected VA gain shown in BRAVO and
CRUISE studies. This cut-off is somewhat arbitrary and one
can discuss if VA low-response criteria are too harsh or if even
a VA gain of, for example, 8 letters should be considered a
low-response based on the prospective study data of BRAVO
and CRUISE [3, 4]. The same argumentation accounts for
reduction in CRT. Less than 30% reduction of CRT was
chosen as the definition for low-response. Many eyes that are
treatment na¨ıve show significant macular edema with CRT
values more than twice as high as unaffected eyes. In our
study, no significant differences were found in baseline CRT
between responder and low-responder at any time point.
However, there was a tendency of thinner baseline CRT
values in the low-responder group. One can argue that these
patients are less likely to show a reduction of CRT of >30%
since they start with thinner CRT. The same accounts for
VA gain. Patients starting with higher baseline VA values are
less likely gaining letters than patient with very low baseline
VA values. In fact, when looking at VA low-responders and
responders after the loading phase, low-responder patients
had a significant higher VA at baseline (58.5 versus 43.2
letters; 𝑝 = 0.027).
Nevertheless, a certain percentage of retinal vein occlu-
sion patients show low-response to anti-VEGF treatment.
Noma et al. published two studies measuring VEGF and
Interleukin 6 (IL6) levels in the vitreous of eyes with CRVO
and BRVO [8, 9]. Mean levels of VEGF and IL6 were
increased in these eyes and correlated with the extent of
retinal nonperfusion and the severity of macular edema.
In addition, these studies revealed that approximately 30%
of eyes showed similar (normal) VEGF values that were
comparable to healthy controls. It might be coincidental that
the numbers of eyes with retinal vein occlusion and “normal”
VEGF levels in the “Noma studies” match our numbers of
anti-VEGF low response. On the other hand, one can hypoth-
esize that anti-VEGF treatment in eyes with normal VEGF
values might not be as effective as in eyes with high VEGF
levels. To prove this hypothesis, a prospective study would be
required which includes VEGF level measurements prior to
treatment. In our study population, no VEGF measurements
have been performed.
Recently, new drugs became available for treating mac-
ular edema in eyes with retinal vein occlusion. Ozurdex, a
biodegradable dexamethasone implant has been shown to be
effective in reducing macular edema and improving patient’s
vision in a prospective randomized trial [10]. Although
intravitreal dexamethasone has been shown to reduce intrav-
itreal VEGF level, it mainly shows anti-inflammatory actions
by blocking phospholipase A2 and inhibition of ICAM,
IL6, and other cytokines [11–13]. In addition, intravitreal
steroids increase the integrity of tight junctions [14]. One can
hypothesize that eyes with macular edema due to retinal vein
occlusion with normal VEGF levels in the vitreous might not
respond well to anti-VEGF treatment but might profit from
anti-inflammatory treatment by intravitreal steroid injection.
Recently, Tservakis et al. published a small case series of 10
eyes with persistent macular edema after anti-VEGF treat-
ments thatwere switched to intravitreal dexamethasone.Nine
out of 10 cases showed improvement in best-correctedVAand
reduction of CRT [15]. However, a prospective, randomized
trial is required to show if a switch from an anti-VEGF to an
anti-inflammatory drug is beneficial in low-responder eyes.
This study has some limitations. First, this was a retro-
spective study designwith a relatively small study population.
Second, patients that were switched to other intravitreal treat-
ments during the observational period have been excluded
in order to assess solely the effect of ranibizumab on VA
6 Journal of Ophthalmology
and CRT. Therefore, the study population is biased and the
rate of low-response to treatment might be underestimated.
Third, no VEGF levels were assessed in our study group.
In addition, other morphological changes or baseline values
such as the presence of retinal hemorrhages, hard exudates,
or concomitant diseases have not been analyzed.
5. Conclusion
In conclusion, approximately 30% of patients with macular
edema due to retinal vein occlusion showed a low response to
ranibizumab treatment after the loading phase and after 1 year
of treatment. Two-thirds of patients that were low-responders
after the loading phase remained low-responders after 1 year
of treatment. Based on our data, a switch of therapy to another
intravitreal drug should be considered after the loading phase
if a low response is observed. A prospective, randomized
comparative trial is needed to find out which therapy switch
might actually be beneficial for our patients.
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